IP Library › Granted Patent US 8,889,628
Granted Patent B2
US 8,889,628 · App. 13/688,187 · Granted Nov 18, 2014

Soluble tandem selectin glycoprotein ligand molecules

Inventor: Gray D Shaw (Redwood City, CA)
C07K14/705C07K19/00C07K14/70564C07K14/70596C07K2319/00C07K2319/02C07K2319/30C07K2319/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,889,628
App. No.
13/688,187
Granted
Nov 18, 2014
Kind
B2
Abstract

Recombinant proteins comprised of multiple selectin binding domains derived from the glycopeptide PSGL-1, in a novel tandem configuration, are disclosed, including their fusions with immunoglobulins and/or other polypeptides. Polynucleotides encoding such proteins, compositions and kits containing such proteins, and methods of using such proteins are also disclosed.

Claims (12)

1. A soluble tandem selectin glycoprotein ligand (TSGL) molecule comprising at least two sulfated P-selectin glycoprotein ligand-1 (PSGL-1) domains combined in a tandem configuration along the same polypeptide chain, wherein each of the PSGL-1 domains comprises amino acids 10 to 16 of SEQ ID NO: 2.

2. The TSGL molecule of claim 1 fused to a non-TSGL polypeptide.

3. The TSGL molecule of claim 1 fused to a non-TSGL polypeptide, wherein the non-TSGL polypeptide is an immunoglobulin Fc.

4. The TSGL molecule of claim 1 , wherein each of the PSGL-1 domains comprises one or more additional amino acids.

5. A soluble tandem selectin glycoprotein ligand (TSGL) immunoglobulin Fc fusion molecule comprising at least two P-selectin glycoprotein ligand-1 (PSGL-1) domains combined in a tandem configuration along the same polypeptide chain, wherein each of the PSGL-1 domains comprises amino acids 10 to 16 of SEQ ID NO: 2.

6. The TSGL immunoglobulin Fc fusion molecule of claim 5 , wherein each of the PSGL-1 domains comprises one or more additional amino acids.

7. The TSGL molecule of claim 1 , wherein each of the PSGL-1 domains comprises amino acids 9 to 19 of SEQ ID NO:2.

8. The TSGL molecule of claim 1 , wherein each of the PSGL-1 domains comprises amino acids 6 to 19 of SEQ ID NO:2.

9. The TSGL molecule of claim 1 , wherein each of the PSGL-1 domains comprises the amino acid sequence of SEQ ID NO: 2.

10. The TSGL immunoglobulin Fc fusion molecule of claim 5 , wherein each of the PSGL-1 domains comprises amino acids 10 to 16 of SEQ ID NO: 2.

11. The TSGL immunoglobulin Fc fusion molecule of claim 5 , wherein each of the PSGL-1 domains comprises the amino acid sequence of SEQ ID NO: 2.

12. The TSGL immunoglobulin Fc fusion molecule of claim 5 , comprising (1) a first PSGL-1 domain comprising the amino acid sequence of SEQ ID NO: 2; (2) a first linker sequence; (3) a second PSGL-1 domain comprising amino acids 9 to 19 of SEQ ID NO: 2; (4) a second linker sequence; and (5) an immunoglobulin Fc fragment.

Continuity (2)
Provisional Application 61564275 · Nov 28, 2011
Related Publication 20130136741A1 · May 30, 2013